Abstract
Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.
Author supplied keywords
Cite
CITATION STYLE
Apra, C., Dumot, C., Bourdillon, P., & Pelissou-Guyotat, I. (2019, June 1). Could propranolol be beneficial in adult cerebral cavernous malformations? Neurosurgical Review. Springer Verlag. https://doi.org/10.1007/s10143-018-01074-0
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.